Interstitial Cystitis Pipeline Landscape Analysis of 08+ Companies by DelveInsight

October 04 19:30 2022
Interstitial Cystitis Pipeline Landscape Analysis of 08+ Companies by DelveInsight

DelveInsight’s, “Interstitial Cystitis Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape.

 

Interstitial Cystitis Pipeline landscape is provided which includes the disease overview and Interstitial Cystitis treatment guidelines. The assessment part of the Interstitial Cystitis pipeline report embraces, in depth Interstitial Cystitis commercial assessment and clinical assessment of the pipeline products under development. In the Interstitial Cystitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Cystitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Interstitial Cystitis Pipeline Report

  • DelveInsight’s Interstitial Cystitis Pipeline report depicts a robust space with 08+ active players working to develop 10+ pipeline therapies for various indications.
  • Leading Interstitial Cystitis Companies such as Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and many others
  • The promising Interstitial Cystitis Therapies includes Certolizumab pegol, SI-722, LP-08 80mg, TTI-1612, MN-001, ASP6294, and others
  • Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.
  • SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku’s proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.

 

Request a sample and discover the recent advances in Interstitial Cystitis @ Interstitial Cystitis Pipeline Outlook

 

The Interstitial Cystitis Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Interstitial Cystitis, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Interstitial Cystitis Pipeline Landscape.

 

Interstitial Cystitis Overview

Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men. However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being physically traumatized.

 

Interstitial Cystitis Emerging Drugs

  • Certolizumab pegol: UCB
  • SI-722: Seikagaku Corporation

 

Interstitial Cystitis Pipeline Analysis Report

  • The report provides detailed insights about emerging therapies for the Interstitial Cystitis treatment and the aggregate therapies developed by major pharma companies.
  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Cystitis Treatment.
  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The Interstitial Cystitis Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Interstitial Cystitis market.

The Interstitial Cystitis Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Scope of the Interstitial Cystitis Pipeline Report

  • Coverage- Global
  • Interstitial Cystitis Pipeline Assessment by Phases- Late stage products (Phase III), Mid-stage products (Phase II), Early-stage product (Phase I) along with the details of, Pre-clinical and Discovery stage candidate, Discontinued & Inactive Candidates
  • Interstitial Cystitis Pipeline Assessment by Route of Administration- Oral, Parenteral, Intravitreal, Subretinal, Topical, Molecule Type
  • Interstitial Cystitis Pipeline Assessment by Molecule Type- Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy, Product Type
  • Interstitial Cystitis Companies– Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and many others
  • Interstitial Cystitis Therapies-Certolizumab pegol, SI-722, LP-08 80mg, TTI-1612, MN-001, ASP6294, and others

 

Dive deep into rich insights for Interstitial Cystitis Pipeline Assessment, Visit @ Interstitial Cystitis Pipeline Therapeutics Assessment

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Interstitial Cystitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Certolizumab pegol: UCB
  8. Mid Stage Products (Phase II)
  9. Drug name: Company name
  10. Early Stage Products (Phase I)
  11. Drug name: Company name
  12. Preclinical and Discovery Stage Products
  13. LYT 503: PureTech Health
  14. Inactive Products
  15. Interstitial Cystitis Key Companies
  16. Interstitial Cystitis Key Products
  17. Interstitial Cystitis- Unmet Needs
  18. Interstitial Cystitis- Market Drivers and Barriers
  19. Interstitial Cystitis- Future Perspectives and Conclusion
  20. Interstitial Cystitis Analyst Views
  21. Interstitial Cystitis Key Companies
  22. Appendix

 

For further information on the Interstitial Cystitis Pipeline therapeutics, reach out @ Interstitial Cystitis Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/